{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-018582","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.731409+00:00","generated_at":"2026-05-16T01:10:57.212755+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Avenue Therapeutics licenses ATX-04 from Duke University for Pompe disease; plans late-stage development","bullets":["Exclusive worldwide license from Duke for ATX-04 (clenbuterol) to treat Pompe disease as adjunct to ERT.","Upfront payment plus development, regulatory, and commercial milestone payments; tiered low single-digit royalty on net sales.","Prior Duke clinical study showed ATX-04 improved six-minute walk distance, respiratory muscle strength, and reduced glycogen.","Avenue to assume IND and FDA orphan drug designation for Pompe disease; plans late-stage development leveraging existing data."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-018582","json":"https://secwatch.observer/filing/0001104659-26-018582.json","markdown":"https://secwatch.observer/filing/0001104659-26-018582.md","text":"https://secwatch.observer/filing/0001104659-26-018582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465926018582/0001104659-26-018582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465926018582/tm267053d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:10:57.212755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}